E
ABIVAX Société Anonyme ABVX
$5.94 $0.020.34%
Recommendation
Sell
Prev Close
$5.92
Volume
477,305
Avg Vol (90D)
177,497
Market Cap
$372.90M
Dividend & Yield
--
52-Week Range
$5.50 - $17.02
P/E (TTM)
--
EPS (TTM)
-$3.47
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Excellent
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
ABIVAX Soci t Anonyme (NASDAQ:ABVX) Given Consensus Rating of "Buy" by Brokerages
3/14/2025 - MarketBeat
ABIVAX Soci t Anonyme (NASDAQ:ABVX) Stock Price Up 4.6% - What's Next?
3/7/2025 - MarketBeat
Wall Street Analysts See a 360.53% Upside in Abivax SA Sponsored ADR (ABVX): Can the Stock Really Move This High?
2/27/2025 - Zacks Investment Research
Abivax Announces Share and Voting Rights Update
2/25/2025 - TipRanks Financial Blog
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
2/21/2025 - GuruFocus
Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025
2/21/2025 - Globe Newswire
ABIVAX Soci t Anonyme (NASDAQ:ABVX) Receives Average Rating of "Buy" from Brokerages
2/17/2025 - MarketBeat
Kepler Capital Reaffirms Their Buy Rating on Abivax SA (0RA9)
2/13/2025 - TipRanks Financial Blog
Wall Street Analysts Think Abivax SA Sponsored ADR (ABVX) Could Surge 427.9%: Read This Before Placing a Bet
2/11/2025 - Zacks Investment Research
ABIVAX Soci t Anonyme (NASDAQ:ABVX) Shares Purchased by abrdn plc
2/10/2025 - MarketBeat
Abivax management to meet with Piper Sandler
2/5/2025 - The Fly
Here's Why Abivax SA Sponsored ADR (ABVX) is Poised for a Turnaround After Losing -19.81% in 4 Weeks
1/30/2025 - Zacks Investment Research
Morgan Stanley Sticks to Its Hold Rating for Abivax SA Sponsored ADR (ABVX)
1/28/2025 - TipRanks Financial Blog
Abivax Releases 2025 Financial Communication Schedule
1/28/2025 - TipRanks Financial Blog
Abivax Publishes 2025 Financial Calendar
1/28/2025 - GuruFocus
Abivax Publishes 2025 Financial Calendar
1/28/2025 - Globe Newswire
Abivax Discloses Share Capital and Voting Rights Information
1/27/2025 - TipRanks Financial Blog
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 ...
1/23/2025 - GuruFocus
Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress
1/23/2025 - Globe Newswire
ABIVAX Soci t Anonyme (NASDAQ:ABVX) Receives Average Recommendation of "Buy" from Analysts
1/23/2025 - MarketBeat
ABIVAX Soci t Anonyme (NASDAQ:ABVX) Short Interest Update
1/15/2025 - MarketBeat
Kepler Capital Sticks to Their Buy Rating for Abivax SA (0RA9)
1/12/2025 - TipRanks Financial Blog
ABIVAX Soci t Anonyme (NASDAQ:ABVX) Earns "Market Outperform" Rating from JMP Securities
1/10/2025 - MarketBeat
Abivax SA: Strong Progress in Phase 3 Trials and Solid Financial Position Justify Buy Rating
1/9/2025 - TipRanks Financial Blog
Abivax Achieves Significant Progress in Phase 3 Ulcerative Colitis Trial
1/9/2025 - TipRanks Financial Blog
Income Statement
Total Revenue (TTM)
$9.77M
EBITDA (TTM)
-$183.76M
EBIT (TTM)
-$184.09M
Net Income (TTM)
-$191.94M
Balance Sheet
Total Assets (Q)
$304.82M
Total Debt (Q)
$121.46M
Total Liabilities (Q)
$169.32M
Book Value Per Share (Q)
$2.15
Cash Flow
Cash from Operations (TTM)
-$167.34M
Cash from Investing (TTM)
$7.64M
Cash from Financing (TTM)
$280.16M
Net Change in Cash (TTM)
$116.89M
Filings
Filing Date
Monday, September 9, 2024
Period Date
Sunday, June 30, 2024
Next Filing
Beginning of April (est)
Price History
Loading...
Beta
--
7-Day Total Return
-24.33%
30-Day Total Return
0.68%
60-Day Total Return
-16.46%
90-Day Total Return
-42.44%
Year to Date Total Return
-18.52%
1-Year Total Return
-54.52%
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Jan 29, 2025 - $5.50
52-week High
Mar 20, 2024 - $17.02
Valuation
Market Cap
$372.90M - Small Cap
Enterprise Value
$253.95M
Price/Sales (TTM)
38.14
Price/Book (Q)
2.75
Dividends and Shares
Shares Outstanding
62.92M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.abivax.com
Phone Number
33 1 53 83 09 63
Address
7-11 boulevard Haussmann
Paris, 75009
Country
France
Year Founded
2013
Business Description
Sector
--
Industry
--
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stablize the immune response in... more
NASDAQ 03/14/2025 4:00PM Eastern Quotes delayed
Weiss Ratings